Jaypirca

Jaypirca is a cancer medicine used to treat adults with mantle cell lymphoma (a cancer of B cells, a type of white blood cell) whose cancer has come back (relapsed) or no longer responds to treatment (refractory), and who had previously received a type of cancer medicine called a Bruton’s tyrosine kinase (BTK) inhibitor. Mantle cell lymphoma is rare, and Jaypirca was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2021. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2450). Jaypirca contains the active substance pirtobrutinib.